Best for
All-rounder
How to buy Agios Pharmaceuticals shares | $35.28
Own Agios Pharmaceuticals shares in just a few minutes.
Agios Pharmaceuticals, Inc is a biotechnology business based in the US. Agios Pharmaceuticals shares (AGIO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $35.28 – an increase of 0.34% over the previous week. Agios Pharmaceuticals employs 536 staff and has a trailing 12-month revenue of around $194.6 million.
How to buy shares in Agios Pharmaceuticals
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: AGIO in this case.
- Research Agios Pharmaceuticals shares. The platform should provide the latest information available.
- Buy your Agios Pharmaceuticals shares. It's that simple.
Best for
Low-cost trading
Best for
US shares
Best for
Beginners
What's in this guide?
- Can I buy shares in Agios Pharmaceuticals?
- Has coronavirus impacted Agios Pharmaceuticals shares?
- Agios Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Agios Pharmaceuticals stock a buy or sell?
- Agios Pharmaceuticals performance over time
- Can I short Agios Pharmaceuticals shares?
- Agios Pharmaceuticals's financials
- How volatile are Agios Pharmaceuticals shares?
- Does Agios Pharmaceuticals pay a dividend?
- Other common questions
How has Coronavirus impacted Agios Pharmaceuticals's share price?
Since the stock market crash in March caused by coronavirus, Agios Pharmaceuticals's share price has had significant negative movement.
Its last market close was $35.28, which is 33.57% down on its pre-crash value of $53.11 and 27.03% up on the lowest point reached during the March crash when the shares fell as low as $27.774.
If you had bought $1,000 worth of Agios Pharmaceuticals shares at the start of February 2020, those shares would have been worth $686.25 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $711.24.
Agios Pharmaceuticals share price
Use our graph to track the performance of AGIO stocks over time.Agios Pharmaceuticals shares at a glance
Information last updated 2020-12-27.
| Latest market close | $35.28 |
|---|---|
| 52-week range | $27.774 - $56.75 |
| 50-day moving average | $40.7265 |
| 200-day moving average | $42.5999 |
| Wall St. target price | $62.91 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-6.673 |
Invest in Agios Pharmaceuticals shares with 0% commission
Other fees may apply. Your capital is at risk.
- Unlimited trades, with no dealing charges or management fees
- If your trades get copied you can earn extra money
- Create an account today in a few minutes
Go to site
Capital at risk
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is it a good time to buy Agios Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Agios Pharmaceuticals price performance over time
Historical closes compared with the last close of $34.4
| 1 week (2021-01-08) | -24.94% |
|---|---|
| 1 month (2020-12-16) | 1.09% |
| 3 months (2020-10-16) | -4.10% |
| 6 months (2020-07-16) | -33.68% |
| 1 year (2020-01-16) | -33.27% |
|---|---|
| 2 years (2019-01-16) | -38.79% |
| 3 years (2018-01-16) | -50.00% |
| 5 years (2016-01-15) | -31.68% |
Agios Pharmaceuticals financials
| Revenue TTM | $194.6 million |
|---|---|
| Gross profit TTM | $-294,299,000 |
| Return on assets TTM | -25.64% |
| Return on equity TTM | -71.51% |
| Profit margin | -170.65% |
| Book value | $6.943 |
| Market capitalisation | $3.1 billion |
TTM: trailing 12 months
How to short and sell Agios Pharmaceuticals shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "AGIO.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 5.4 million Agios Pharmaceuticals shares held short by investors – that's known as Agios Pharmaceuticals's "short interest". This figure is 9.6% up from 5.0 million last month.
There are a few different ways that this level of interest in shorting Agios Pharmaceuticals shares can be evaluated.
Agios Pharmaceuticals's "short interest ratio" (SIR)
Agios Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Agios Pharmaceuticals shares currently shorted divided by the average quantity of Agios Pharmaceuticals shares traded daily (recently around 752696.12188366). Agios Pharmaceuticals's SIR currently stands at 7.22. In other words for every 100,000 Agios Pharmaceuticals shares traded daily on the market, roughly 7220 shares are currently held short.
However Agios Pharmaceuticals's short interest can also be evaluated against the total number of Agios Pharmaceuticals shares, or, against the total number of tradable Agios Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agios Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Agios Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.1214% of the tradable shares (for every 100,000 tradable Agios Pharmaceuticals shares, roughly 121 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Agios Pharmaceuticals.
Find out more about how you can short Agios Pharmaceuticals stock.
Agios Pharmaceuticals share dividends
We're not expecting Agios Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Agios Pharmaceuticals share price volatility
Over the last 12 months, Agios Pharmaceuticals's shares have ranged in value from as little as $27.774 up to $56.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agios Pharmaceuticals's is 1.8094. This would suggest that Agios Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Win £500 to get your trading started
Subscribe to trending stock alerts for a chance to win
Agios Pharmaceuticals overview
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Frequently asked questions
More guides on Finder
-
How to buy Agios Pharmaceuticals shares
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Charlie’s Holdings shares
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Lemonade shares | $50.05
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Unity Software shares | $111.51
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
-
How to buy FuelCell Energy shares | $3.745
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Agios Pharmaceuticals shares | $0.1275
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
-
How to buy Zomedica Pharmaceuticals shares | $0.93
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
-
How to buy YRC Worldwide shares | $4.66
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
-
How to buy Xeros Technology Group shares | 220p
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
-
How to buy Xpediator shares | 33.5p
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ask an Expert